Summit, Akeso's ivonescimab shows smaller benefit with longer follow-up in China

RegulatoryapprovedivonescimabNegative

AI Analysis

Summary

Summit Therapeutics and Akeso received China approval for ivonescimab in first-line lung cancer, but updated data from longer follow-up shows a smaller clinical benefit than previously observed.

Outcome Details

China approval for first-line lung cancer patients with smaller benefit observed in longer follow-up data

Importance:6/10

Sentiment:

-0.30

China approvallung canceroncologyregulatory

Related Companies

$GBIO $CHHE $TRAX

Read the original article

Published by Endpoints News on August 17, 2026 2:48 PM

Read Original